This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Covance Appoints Dr. Steve Street To Lead Worldwide Safety Assessment And Pharmaceutical Chemistry Services

Stocks in this article: CVD

PRINCETON, N.J., June 18, 2012 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today announced that Steve Street, Ph.D., has joined the company as Global Vice President and General Manager, overseeing Covance's worldwide safety assessment and pharmaceutical chemistry services.  He will be based in Harrogate, UK. Dr. Street, with more than 27 years of experience in biopharmaceutical R&D, joins Covance from Pfizer, Inc., where he served as Vice President and Head of two global R&D units – the Research Centers of Emphasis and Continuous Improvement.  In these roles, he led the company's high-performing technology and operations group to increased portfolio development speed and project survival, ultimately creating a positive impact across multiple therapeutic areas, including chemistry and biology outsourcing, innovation, and new indications.  During his tenure at Pfizer, Dr. Street also served as Head of the company's Worldwide Chemistry Discipline.

"Steve's keen strategic insights and exceptional R&D background will benefit Covance as we refine our global presence and strengthen our scientific expertise in early development," said Deborah Tanner, Executive Vice President and Group President, R&D Laboratories, Covance.  "Science is at the core of everything we do, and the addition of a leader like Steve allows us to continue to meet clients' needs in this increasingly complex industry and, ultimately, remain the drug development partner of choice."

"Covance is known for its continuous global innovation in development, superior quality of products and services, and long-standing client relationships, all of which are essential elements for sustained success in today's highly competitive R&D landscape," said Dr. Street. "With an increasing focus on outsourcing, this is a very exciting time to transition from pharma to a contract research organization, and I am proud to join the industry leader.  I look forward to learning from and working with a talented, dedicated group of new colleagues at Covance."

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs